Drug Trial Radar · NCT06997068
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Aug 7, 2025
Primary completion
Aug 5, 2029
Study completion Aug 5, 2029
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic) among rural Midwest patients. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving the combination of methotrexate, erlotinib, and celecoxib may be feasible, safe, and effective in treating rural Midwest patients with recurrent/metastatic head and neck cancer.
Conditions
- Metastatic Oral Cavity Carcinoma
- Recurrent Oral Cavity Carcinoma
- Stage IVC Lip and Oral Cavity Cancer AJCC v8
- Head and Neck Cancer
- Hypopharynx Cancer
- Oropharynx Cancer
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Metastatic Hypopharyngeal Carcinoma
- Metastatic Laryngeal Carcinoma
- Metastatic Malignant Head and Neck Neoplasm
- Metastatic Oropharyngeal Carcinoma
- Recurrent Hypopharyngeal Carcinoma
- Recurrent Laryngeal Carcinoma
- Recurrent Malignant Head and Neck Neoplasm
- Recurrent Oropharyngeal Carcinoma
- Stage IVC Hypopharyngeal Carcinoma AJCC v8
- Stage IVC Laryngeal Cancer AJCC v8
- Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
CelecoxibDrug
Given PO
Erlotinib HydrochlorideDrug
Given PO
Imaging ProcedureProcedure
Undergo SOC imaging scans
InterviewOther
Ancillary studies
MethotrexateDrug
Given PO
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rates of provider referral and patient enrollment (Feasibility)Time frame: Up to 2 years
- Rate of retention (Feasibility)Time frame: Up to 2 years
- Rate of conversion from virtual to in-person visits (Feasibility)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.